1 / 25

Viagra RFID Project AIDC Conference

Viagra RFID Project AIDC Conference. October 5, 2006. Rich Hollander Senior Director, Packaging Services. Tim Marsh Manager, Global Package Technology and Testing. Original Project Objective.

lave
Download Presentation

Viagra RFID Project AIDC Conference

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Viagra RFID ProjectAIDC Conference October 5, 2006 Rich Hollander Senior Director, Packaging Services Tim Marsh Manager, Global Package Technology and Testing

  2. Original Project Objective By year-end 2005, incorporate RFID tags into the packaging of all Viagra trade product destined for the U.S. market. Provide a means to authenticate at the pharmacylevel. Viagra® (sildenafil citrate) is a registered trademark of Pfizer Inc.

  3. Why are we doing this? • Patient Safety – Deter counterfeiting • FDA Guidance • Regulatory (pedigree) requirements • Customer drivers • Pedigree compliance • Operational benefits

  4. Why Viagra? • Viagra is Pfizer’s most highly counterfeited product • Viagra is produced on one line, in one facility • The volume of Viagra is reasonable • Consistent with FDA guidance regarding the tagging of highly counterfeited items in 2005 Viagra® (sildenafil citrate) is a registered trademark of Pfizer Inc.

  5. What is being done? • A unique ID (EPC #) is associated with every Viagra bottle, case and pallet distributed in the U.S. • High frequency (13.56 MHz) RFID tags are being utilized on the bottles and ultra high frequency (915 MHz) RFID tags on the Viagra cases and pallets • An RFID tag and DataMatrix (2D) bar code is incorporated into the labeling of every Viagra bottle • Linear bar codes for case and pallet RFID backup Viagra® (sildenafil citrate) is a registered trademark of Pfizer Inc.

  6. RFID High Frequency Tag

  7. Viagra Label Viagra® (sildenafil citrate) is a registered trademark of Pfizer Inc.

  8. Item Level Label Tag INSERT REVISED IMAGE OF RFID BOTTLE LABEL WITH HF TAG ILLUSTRATION 2D Data Matrix with EPC Number RFID Tag Embedded in Label with EPC Number

  9. Case Level Label Tag INSERT REVISED IMAGE OF CASE w/ UHF Label & Wrap-Around HDMA Label RFID Tag Embedded in Label with Additional Code 128 Barcode; both with EPC Number

  10. What else was done? • Modifying our packaging operations • Reading and writing to the tags on-line (not prewritten tags and not applied in the DC) • Capturing information about the EPC at the point of commissioning, shipping, and as it’s authenticated • Modifying our logistics operations to ship from all U.S. Pfizer logistics centers • Enabling an authentication capability for wholesale, retail, pharmacy use

  11. Labeling Operation in France

  12. RFID Item level tag on Label

  13. Viagra RFID • Key Decisions Made During Implementation • Utilize HF tags at the item level and UHF at the case and pallet level • Read and Write to tags online vs. prewritten tags (scaleable) • Develop a means to uniquely identify each bottle, case and pallet on line • Incorporate a redundant 2D bar code into the labeling • Modify packaging and logistics operations • Leverage existing technology • Minimize data integration • Implement an authentication service • Adopt EPC numbering scheme without NDC (privacy) • Disclose use of RFID on Viagra label • Enable all 3 Logistics Centers to ship tagged product

  14. Viagra RFID Early Learnings • RFID Implementation is costly and complex – in excess of 75 people involved during past year at a cost of approximately $5 million • There is much yet to be learned about the technology and process implications • Additional experience with tagged product in the market is required • The Cost/Benefit around RFID is not yet clear • Key Decisions are required about how the technology is to be deployed – some (deter counterfeiting of high risk items) vs. all items (track and trace all products/pedigree) • Pleased with our choice of frequencies and internal performance thus far • Few trading partners are ready to read tagged product • Many Manufacturers and others have adopted a “wait-and-see” approach

  15. Key “Take Away” Points • This is a Patient Safety initiative • Technology alone will not deter counterfeiting • Authentication verifies the EPC authenticity not the product authenticity • We are using passive RFID tags and will not be collecting any patient level information • We will NOT be spying on patients

  16. Other Viagra RFID Key Messages • Technology is only one component of an overall strategy required to address counterfeiting • Action must also be taken to address business practices, legislative and regulatory solutions, and enhanced enforcement • RFID offers promise to further secure the supply chain but will require a significant investment throughout the supply chain and years to implement • We believe mass serialization of items affords the greatest protection against counterfeiting when coupled with the secure exchange of information about the physical movement of the product

  17. RFID 2006 • Assess performance of the Viagra tagged product in the market • Work with trading partners and collect metrics; ongoing informal feedback and formal quarterly surveys • Encourage additional retail and wholesale participation • Assess acceptance of the technology in the market • Evaluate track-and-trace capability vs. EPC authentication • Continue to drive for industry standards regarding tags, frequencies, and data exchange • Address data sharing issues

  18. RFID Strategy • 3Q 2006 Analysis to include the following: • Data regarding market usage and impact, lessons learned, etc. • Technology assessment • Track-and- trace outlook vs. authentication • Customer acceptance • Other potential applications (return goods, recalls, pedigree compliance, other operational efficiencies) • Regulatory requirements (Manufacturers and others) • External environment • Cost/Benefit Analysis (data integration, validation, etc) • Decision on continued Viagra tagging • Recommendations regarding the technology and other Pfizer brands

  19. Beyond 2006 • Based on 2006 findings….. • Target additional products for mass serialization (2D, RFID, other) using a risk-based approach • “Partner” with select trading partners and technology vendors to advance the mass serialization of items and create greater value (inventory visibility/planning) • Continue to assess the technology and its ability to deter counterfeiting (RFID tags being counterfeited?)

  20. E- Authentication Authentication Features and Sample Screens

  21. Verification Summary

  22. Bulk Authentication Results

  23. Unrecognized EPC

  24. Thank you!

More Related